Fibroblast activation protein (FAP), a transmembrane serine protease, is overexpressed in cancer associated fibroblasts (CAFs) in the stromal component of most carcinomas. Due to its absence or low expression level in normal tissues, FAP represents a promising cancer diagnostic marker and therapeutic target. Our lab is actively exploring the use of radiolabeled FAP-targeting pharmacophores for imaging and radiotherapy of cancer.
Development of FAP-targeting Radiopharmaceuticals
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.